PMID- 10582701
OWN - NLM
STAT- MEDLINE
DCOM- 19991214
LR  - 20071114
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 59
IP  - 22
DP  - 1999 Nov 15
TI  - Human leukocyte antigen class I expression on squamous cell carcinoma cells 
      regulates natural killer cell activity.
PG  - 5793-9
AB  - Human leukocyte antigen (HLA) class I molecules on hematopoietic cancers and 
      melanomas inhibit attack by natural killer lymphocytes, but previous studies have 
      not consistently demonstrated that carcinoma cells are protected by HLA class I 
      expression. We investigated whether HLA class I molecules protect oral and 
      pharyngeal squamous cell carcinoma cells from natural killer lymphocyte attack. 
      Squamous cell carcinoma cell lines expressed varying levels of HLA class I, which 
      correlated inversely with cytolysis by natural killer-enriched polyclonal 
      lymphocytes. Cytolysis was increased by the presence of anti-HLA class I blocking 
      monoclonal antibody (mAb). Subclones of the NK-92 human natural killer lymphoma 
      cell line were derived by treatment with 5-aza-2'-deoxycytidine and limiting 
      dilution cloning. NK-92 subclones expressed distinct sets of HLA class I-specific 
      receptors. Some NK-92 subclones differentially lysed hematopoietic cells and 
      squamous cell carcinoma cells, even in the presence of anti-HLA class I blocking 
      mAb. This suggests that natural killer cells recognize different non-HLA ligands 
      on hematopoietic and squamous cell carcinoma cells. In the presence of anti-HLA 
      class I monoclonal antibody, other NK-92 subclones increased cytolysis of 
      squamous cell carcinoma cells with moderate-to-high HLA class I levels. Anti-HLA 
      class I mAb also increased natural killer cell attack of squamous cell carcinoma 
      cells that were adherent to plastic. These data suggest that natural killer cell 
      recognition of squamous cell carcinoma cells depends upon the balance of 
      stimulatory and inhibitory ligands.
FAU - Lutz, C T
AU  - Lutz CT
AD  - Department of Pathology, University of Iowa, Iowa City 52242-1182, USA.
FAU - Kurago, Z B
AU  - Kurago ZB
LA  - eng
GR  - R01 DE11139/DE/NIDCR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Epitopes)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Alleles
MH  - Carcinoma, Squamous Cell/*immunology
MH  - Epitopes/immunology
MH  - Histocompatibility Antigens Class I/genetics/*immunology
MH  - Humans
MH  - Immunity, Cellular
MH  - Killer Cells, Natural/*immunology
MH  - Lymphoma/immunology
MH  - Mouth Neoplasms/*immunology
MH  - Pharyngeal Neoplasms/*immunology
MH  - Tumor Cells, Cultured
EDAT- 1999/12/03 00:00
MHDA- 1999/12/03 00:01
CRDT- 1999/12/03 00:00
PHST- 1999/12/03 00:00 [pubmed]
PHST- 1999/12/03 00:01 [medline]
PHST- 1999/12/03 00:00 [entrez]
PST - ppublish
SO  - Cancer Res. 1999 Nov 15;59(22):5793-9.